Abraham, Fruchter & Twersky, LLP today announced that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of the purchasers of China Medicine Corporation (“China Medicine” or the “Company”) (OTCBB: CHME) common stock between November 30, 2006 and March 23, 2011 (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from July 18, 2011. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Jack G. Fruchter, Jeffrey S. Abraham or Philip T. Taylor at (212) 279-5050 or (800) 440-8986, or via e-mail at firstname.lastname@example.org or email@example.com. Any member of the putative class may move the Court to serve as lead plaintiff through the counsel of their choice, or may choose to do nothing and remain an absent class member. The complaint charges China Medicine and certain of its officers and directors with violations of the Securities Exchange Act of 1934. China Medicine is engaged in the distribution and manufacturing of traditional Chinese medicines in the People’s Republic of China. The Complaint alleges that during the Class Period, defendants issued materially false and misleading statements regarding the Company’s business and financial results. As a result of defendants’ false statements, China Medicine stock traded at artificially inflated prices during the Class Period. On February 22, 2011, China Medicine issued a press release announcing that Frazer, LLP, the Company’s accountant, would be declining to stand for reappointment. On the news, the Company’s stock lost more than 40% of its value from February 23, 2010 to March 23, 2011. Then on March 23, 2011, China Medicine filed a Form 8-K with the Securities and Exchange Commission (“SEC”) announcing that its board of directors (the “Board”) had concluded that the Company’s financial statements filed with the SEC for the 2008 and 2009 fiscal years and the quarterly reports during the fiscals years 2008, 2009 and 2010 were unreliable. China Medicine also disclosed that certain accounting and reporting errors were identified with respect to improper activities by certain employees at the Company’s subsidiaries. The Company purportedly intends to restate the previously issued financial statements and has withdrawn its application for a NASDAQ listing. In reaction to the news, on the next trading day, China Medicine’s stock drooped by over 53% from $1.16 per share on March 23, 2011 to $0.54 per share on March 24, 2011 on heavy volume. On July 8, 2011, the Company announced that its earlier financial statements for the 2006 and 2007 fiscal years were also considered materially unreliable. In reaction, China Medicine’s stock lost 10% closing at $0.72 per share down from $0.80 per share on July 8, 2011.
According to the complaint, the true facts, which were known by defendants but concealed from the investigating public during the Class Period, were as follows: (a) the company’s employees were engaged in improper activities with respect to financial reporting; (b) the financial reports filed with the SEC and the related statements made to investors were materially inaccurate and unreliable; and (c) defendant Frazer failed to conduct its audits of the Company’s financial statements according to standards promulgated by the Public Company Accounting Oversight Board or the Auditing Standards Board.Plaintiff seeks to recover damages on behalf of all purchasers of China Medicine common stock during the Class Period (the “Class”). The plaintiff is represented by Abraham, Fruchter & Twersky, LLP, which has extensive experience in shareholder and securities class action cases, and the firm has been ranked among the leading class action law firms in terms of recoveries achieved by a survey of class action law firms conducted by Institutional Shareholder Services. Contact:Jeffrey S. AbrahamJack G. FruchterPhilip T. TaylorAbraham, Fruchter & Twersky, LLPOne Penn Plaza, Suite 2805New York, N.Y. 10119Telephone: (800) 440-8986